[Spironolactone combined with chlorthalidone in the treatment of essential arterial hypertension].
The antihypertensive effect and the tolerance of the association of spironolactone and chlorthalidone were evaluated clinically and by numerous laboratory examinations in a group of 18 patients affected with non-complicated essential hypertension. All the patients were treated for 30 consecutive days with chlorthalidone (100 mg/day) and then for another 30 days with the two drugs administered contemporaneously (100 mg/day of spironolactone + 100 mg/day chlorthalidone). The balanced combination of the two drugs showed to be significantly more active than the treatment with just chlorthalidone and the margin of safety wider; the therapeutic activity showed to be independent from the variations of the plasma renin activity.
D000368:Aged; D002752:Chlorthalidone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013148:Spironolactone / Q000627:therapeutic use*
D013148:Spironolactone; D002752:Chlorthalidone
Lo spironolattone associato al clortalidone nel trattamento dell'ipertensione arteriosa essenziale